• About
  • Subscribe
  • Advertise
  • Contact
Wednesday, June 25, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

Study highlights biomarker for discontinuing anti-VEGF treatment

by Myles Hume
February 14, 2020
in Macular disease, News, Ophthalmology, Research, Therapeutics
Reading Time: 2 mins read
A A
Share on FacebookShare on Twitter

A new study has demonstrated that a particular biomarker can be used to select which age-related macular degeneration (AMD) patients can discontinue their anti-VEGF therapy.

South Korean researchers recently validated a treat-and-stop (TES) protocol through the identification of OCT-angiography (OCT-A) biomarkers that correspond with recurrent sustained exudation choroidal neovascularisation (CNV).

According to the team both treat-and-extend regimens and the TES protocol have shown comparable effectiveness compared to fixed dosing schedules, however the guidelines for discontinuing treatment are not yet clear.

In total 128 patients with neovascular AMD (nAMD) were enrolled in the study and split into ‘stop treatment’ and ‘continuing treatment’ groups.

The TES protocol was applied to patients who, after three initial monthly injections, were able to extend their treatment. This decision was based on whether their macula had no signs of fluid in an OCT scan and clinical examination.

As soon as the macula was free of fluid, the treatment intervals were successively increased by two weeks until three months had passed. Patients then received two or more injections at three-month intervals, and if the macula remained dry treatments were suspended.

If at any point a new CNV developed or recurrence of the previous CNV was found, treatment was immediately reinitiated.

The researchers concluded the appearance of neovascularisation may be used to determine the prognosis of anti-VEGF therapy response in nAMD patients. They also concluded that TES is reasonable making discontinuing treatment a possibility for some patients.

According to the authors there are no set guidelines for discontinuing treatment. Frequent anti-VEGF therapy can erode the quality of life for nAMD patients and their caregivers’, in addition to financial strain and loss of productivity.

“Our findings have two main consequences: first, confirming the validity of TES regimens and promoting the possibility of discontinuing treatment,” the study said.

“And second, verifying the morphologic pattern of CNV on OCT-A after anti-VEGF treatment as a useful biomarker determining whether to stop anti-VEGF injection or to continue disease suppression by maintenance therapy.”

Tags: age-related macular degenerationAMDanti-VEGF therapybiomarkerCNVneovascularisationOCT-Asouth koreasustained exudation choroidal neovascularisationThe research has promoted the possibility of discontinuing treatment.Treat-and-extendtreat-and-stop

Related Posts

The 2025 meeting is taking place in Melbourne 14-17 November. Image: f11photo/stock.adobe.come & Prime Creative Media.

RANZCO has sights on biggest congress yet in 2025

by Staff Writer
June 24, 2025

RANZCO is anticipating its 2025 congress in Melbourne may be one of the largest yet. Since opening registration on 10...

The CureSight device trains the visual system to use both eyes simultaneously, while the user watches any streamed video content of choice through treatment glasses. Image: BOC Instruments.

CureSight – eye-tracking amblyopia treatment for use at home

by Staff Writer
June 24, 2025

BOC Instruments has announced the launch of a new technology that leverages proprietary eye-tracking technology and cloud-based remote monitoring to...

With support from The Fred Hollows Foundation, Chanthoeun from Cambodia received a pair of special prescription glasses to help with her high myopia and she now conducts basic eyesight tests for her children using skills she learned at the vision centre. Image: Michael Amendolia.

Lancet: Glasses still out of reach for millions of people

by Staff Writer
June 24, 2025

New data released in The Lancet Global Health by the Vision Loss Expert Group and World Health Organisation (WHO) and supported by...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited